RU2015144182A - Пиразоламидное соединение и его применения в медицине - Google Patents
Пиразоламидное соединение и его применения в медицине Download PDFInfo
- Publication number
- RU2015144182A RU2015144182A RU2015144182A RU2015144182A RU2015144182A RU 2015144182 A RU2015144182 A RU 2015144182A RU 2015144182 A RU2015144182 A RU 2015144182A RU 2015144182 A RU2015144182 A RU 2015144182A RU 2015144182 A RU2015144182 A RU 2015144182A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- compound according
- acceptable salt
- paragraphs
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/78—Benzoic acid esters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (22)
1. Соединение, представленное формулой [I]:
в которой n составляет 1 или 2,
или соответствующая фармацевтически приемлемая соль.
2. Соединение, представленное формулой [II] или [IIh]
3. Соединение по п. 2, которое представлено формулой [II]:
4. Соединение по п. 2, которое представлено формулой [IIh]:
5. Соединение, представленное формулой [III]:
6. Фармацевтическая композиция, содержащая соединение по любому из пп. 1-5 или соответствующую фармацевтически приемлемую соль и фармацевтически приемлемый носитель.
7. Ингибитор PDHK, содержащий соединение по любому из пп. 1-5 или соответствующую фармацевтически приемлемую соль.
8. Ингибитор PDHK1, содержащий соединение по любому из пп. 1-5 или соответствующую фармацевтически приемлемую соль.
9. Ингибитор PDHK2, содержащий соединение по любому из пп. 1-5 или соответствующую фармацевтически приемлемую соль.
10. Гипогликемическое средство, содержащее соединение по любому из пп. 1-5 или соответствующую фармацевтически приемлемую соль.
11. Снижающее уровень молочной кислоты средство, содержащее соединение по любому из пп. 1-5 или соответствующую фармацевтически приемлемую соль.
12. Средство для профилактики или лечения таких заболеваний, как диабет, синдром инсулинорезистентности, метаболический синдром, гипергликемия, гиперлактацидемия, диабетические осложнения, сердечная недостаточность, кардиомиопатия, ишемия миокарда, инфаркт миокарда, стенокардия, дислипидемия, атеросклероз, болезнь периферических артерий, перемежающаяся хромота, хроническое обструктивное заболевание легких, ишемия головного мозга, апоплексия головного мозга, митохондриальное заболевание, митохондриальная энцефаломиопатия, рак или легочная гипертензия, которое содержит соединение по любому из пп. 1-5 или соответствующую фармацевтически приемлемую соль.
13. Профилактическое или лекарственное средство по п. 12, в котором диабет представляет собой диабет первого типа или диабет второго типа.
14. Профилактическое или лекарственное средство по п. 12, в котором диабетические осложнения выбираются из группы, которую составляют диабетическая невропатия, диабетическая ретинопатия, диабетическая нефропатия и катаракта.
15. Профилактическое или лекарственное средство по п. 12, в котором сердечная недостаточность представляет собой острую сердечную недостаточность или хроническую сердечную недостаточность.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791164P | 2013-03-15 | 2013-03-15 | |
| JP2013-053195 | 2013-03-15 | ||
| US61/791,164 | 2013-03-15 | ||
| JP2013053195 | 2013-03-15 | ||
| JP2013-127318 | 2013-06-18 | ||
| JP2013127318 | 2013-06-18 | ||
| PCT/JP2014/056825 WO2014142290A1 (ja) | 2013-03-15 | 2014-03-14 | ピラゾール－アミド化合物およびその医薬用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018128304A Division RU2018128304A (ru) | 2013-03-15 | 2014-03-14 | Пиразоламидное соединение и его применения в медицине |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2015144182A true RU2015144182A (ru) | 2017-04-24 |
| RU2015144182A3 RU2015144182A3 (ru) | 2018-03-06 |
| RU2664532C2 RU2664532C2 (ru) | 2018-08-20 |
Family
ID=51536938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015144182A RU2664532C2 (ru) | 2013-03-15 | 2014-03-14 | Пиразоламидное соединение и его применения в медицине |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9040717B2 (ru) |
| EP (3) | EP3805205A1 (ru) |
| JP (6) | JP6208603B2 (ru) |
| KR (1) | KR102226096B1 (ru) |
| CN (1) | CN105051015B (ru) |
| AU (1) | AU2014230569B2 (ru) |
| BR (1) | BR112015022077A2 (ru) |
| CA (1) | CA2904985C (ru) |
| CL (1) | CL2015002608A1 (ru) |
| CY (1) | CY1120173T1 (ru) |
| DK (1) | DK2975028T3 (ru) |
| ES (1) | ES2663789T3 (ru) |
| HK (1) | HK1215808A1 (ru) |
| HR (1) | HRP20180635T1 (ru) |
| HU (1) | HUE036672T2 (ru) |
| IL (1) | IL241355B (ru) |
| LT (1) | LT2975028T (ru) |
| ME (1) | ME03090B (ru) |
| MX (1) | MX2015012743A (ru) |
| MY (1) | MY182884A (ru) |
| NO (1) | NO2975028T3 (ru) |
| PE (1) | PE20151595A1 (ru) |
| PH (1) | PH12015501993A1 (ru) |
| PL (1) | PL2975028T3 (ru) |
| PT (1) | PT2975028T (ru) |
| RS (1) | RS57188B1 (ru) |
| RU (1) | RU2664532C2 (ru) |
| SG (1) | SG11201507327TA (ru) |
| SI (1) | SI2975028T1 (ru) |
| TW (1) | TWI633885B (ru) |
| WO (1) | WO2014142290A1 (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| SG11201505347VA (en) | 2013-01-15 | 2015-08-28 | Incyte Corp | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
| PT2975028T (pt) * | 2013-03-15 | 2018-03-29 | Japan Tobacco Inc | Composto de pirazol-amida e utilizações medicinais para o mesmo |
| US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| CN109476609B (zh) | 2016-07-29 | 2022-06-14 | 日本烟草产业株式会社 | 吡唑-酰胺化合物的制造方法 |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| JP7241556B2 (ja) * | 2018-02-01 | 2023-03-17 | 日本たばこ産業株式会社 | 含窒素複素環アミド化合物及びその医薬用途 |
| EP3851103A4 (en) * | 2018-09-11 | 2022-06-08 | Japan Tobacco Inc. | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CHRONIC KIDNEY DISEASE CONTAINING A PYRAZOLE-AMIDE COMPOUND |
| CN113490492A (zh) | 2019-03-04 | 2021-10-08 | 日本烟草产业株式会社 | 吡唑酰胺化合物的非晶质固体分散体 |
| MX2022010950A (es) * | 2020-03-04 | 2022-10-07 | Japan Tobacco Inc | Compuesto triciclico fusionado y uso farmaceutico del mismo. |
| IL311162A (en) * | 2021-09-01 | 2024-04-01 | Japan Tobacco Inc | A tricyclic compound containing nitrogen and its pharmaceutical use |
| KR20240045387A (ko) * | 2022-09-28 | 2024-04-08 | (주)제이디바이오사이언스 | 신규한 플루오렌 유도체 및 이의 용도 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2827285B1 (fr) * | 2001-07-10 | 2003-12-05 | Rhodia Chimie Sa | Reactif et procede pour la perfluoroalcoylation |
| TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| TW200418825A (en) | 2002-12-16 | 2004-10-01 | Hoffmann La Roche | Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives |
| PT1620118E (pt) | 2003-04-08 | 2014-10-16 | Yeda Res & Dev | Fármacos peguilados de modo reversível |
| CN1842517A (zh) | 2004-02-20 | 2006-10-04 | 安斯泰来制药有限公司 | 芴衍生物 |
| FR2885904B1 (fr) | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
| RU2007147844A (ru) * | 2005-05-23 | 2009-06-27 | Джапан Тобакко Инк. (Jp) | Пиразольное соединение и содержащее его терапевтическое средство для лечения сахарного диабета |
| US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
| FR2936173B1 (fr) * | 2008-09-22 | 2012-09-21 | Snecma | Procede pour la fabrication d'une piece en titane avec forgeage initial dans le domaine beta |
| AR074797A1 (es) | 2008-10-10 | 2011-02-16 | Japan Tobacco Inc | Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial |
| RU2011147232A (ru) * | 2009-04-22 | 2013-05-27 | Астеллас Фарма Инк. | Производное карбоновой кислоты |
| PT2975028T (pt) * | 2013-03-15 | 2018-03-29 | Japan Tobacco Inc | Composto de pirazol-amida e utilizações medicinais para o mesmo |
| US20140296316A1 (en) | 2013-03-15 | 2014-10-02 | Japan Tobacco Inc. | Hydrate and crystal of fluorene compounds |
| TW201536749A (zh) | 2013-07-01 | 2015-10-01 | Japan Tobacco Inc | 吡唑－醇化合物及其醫藥用途 |
| WO2015002118A1 (ja) | 2013-07-01 | 2015-01-08 | 日本たばこ産業株式会社 | フルオレン－アミド化合物およびその医薬用途 |
-
2014
- 2014-03-14 PT PT147633853T patent/PT2975028T/pt unknown
- 2014-03-14 MX MX2015012743A patent/MX2015012743A/es active IP Right Grant
- 2014-03-14 SG SG11201507327TA patent/SG11201507327TA/en unknown
- 2014-03-14 KR KR1020157028869A patent/KR102226096B1/ko active IP Right Grant
- 2014-03-14 BR BR112015022077A patent/BR112015022077A2/pt not_active Application Discontinuation
- 2014-03-14 US US14/210,746 patent/US9040717B2/en active Active
- 2014-03-14 EP EP20204677.7A patent/EP3805205A1/en not_active Withdrawn
- 2014-03-14 JP JP2014050964A patent/JP6208603B2/ja active Active
- 2014-03-14 TW TW103109400A patent/TWI633885B/zh active
- 2014-03-14 RS RS20180492A patent/RS57188B1/sr unknown
- 2014-03-14 NO NO14763385A patent/NO2975028T3/no unknown
- 2014-03-14 CN CN201480016173.0A patent/CN105051015B/zh active Active
- 2014-03-14 SI SI201430703T patent/SI2975028T1/en unknown
- 2014-03-14 MY MYPI2015703124A patent/MY182884A/en unknown
- 2014-03-14 EP EP14763385.3A patent/EP2975028B1/en active Active
- 2014-03-14 WO PCT/JP2014/056825 patent/WO2014142290A1/ja active Application Filing
- 2014-03-14 ES ES14763385.3T patent/ES2663789T3/es active Active
- 2014-03-14 RU RU2015144182A patent/RU2664532C2/ru active
- 2014-03-14 PL PL14763385T patent/PL2975028T3/pl unknown
- 2014-03-14 EP EP18156002.0A patent/EP3348545A1/en not_active Withdrawn
- 2014-03-14 CA CA2904985A patent/CA2904985C/en active Active
- 2014-03-14 HU HUE14763385A patent/HUE036672T2/hu unknown
- 2014-03-14 PE PE2015001993A patent/PE20151595A1/es active IP Right Grant
- 2014-03-14 DK DK14763385.3T patent/DK2975028T3/en active
- 2014-03-14 LT LTEP14763385.3T patent/LT2975028T/lt unknown
- 2014-03-14 AU AU2014230569A patent/AU2014230569B2/en not_active Ceased
-
2015
- 2015-04-22 US US14/692,846 patent/US20160074364A1/en not_active Abandoned
- 2015-09-08 PH PH12015501993A patent/PH12015501993A1/en unknown
- 2015-09-09 IL IL241355A patent/IL241355B/en active IP Right Grant
- 2015-09-11 CL CL2015002608A patent/CL2015002608A1/es unknown
-
2016
- 2016-04-01 HK HK16103742.7A patent/HK1215808A1/zh not_active IP Right Cessation
-
2017
- 2017-09-07 JP JP2017171644A patent/JP2018021061A/ja not_active Ceased
- 2017-10-06 US US15/726,569 patent/US20180256547A1/en not_active Abandoned
-
2018
- 2018-03-14 ME MEP-2018-110A patent/ME03090B/me unknown
- 2018-04-20 CY CY20181100419T patent/CY1120173T1/el unknown
- 2018-04-23 HR HRP20180635TT patent/HRP20180635T1/hr unknown
- 2018-07-05 JP JP2018128272A patent/JP2018188449A/ja not_active Ceased
-
2019
- 2019-06-06 JP JP2019105806A patent/JP2019194197A/ja not_active Ceased
- 2019-07-02 US US16/459,959 patent/US20200163937A1/en not_active Abandoned
-
2020
- 2020-08-05 JP JP2020133190A patent/JP2020189855A/ja not_active Ceased
-
2021
- 2021-09-22 JP JP2021153931A patent/JP2022000453A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015144182A (ru) | Пиразоламидное соединение и его применения в медицине | |
| CY1125006T1 (el) | Λιπαρα οξεα και η χρηση τους σε συνδυασμο με βιομορια | |
| PH12020500613A1 (en) | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes | |
| JP2010529203A5 (ru) | ||
| JP2016500063A5 (ru) | ||
| JP2014511891A5 (ru) | ||
| NZ598294A (en) | Heterocyclic compounds for the inhibition of pask | |
| JP2015517579A5 (ru) | ||
| MY181731A (en) | Azole benzene derivative | |
| JP2019525899A5 (ru) | ||
| AR074619A1 (es) | Derivados de ciclopentilacrilamida | |
| RU2016134749A (ru) | Гетероциклическое сульфонамидное производное и лекарственное средство, содержащее такое производное | |
| JP2017014206A5 (ru) | ||
| JP2018172440A5 (ru) | ||
| JP2015516419A5 (ru) | ||
| JP2013166781A5 (ru) | ||
| JP2018502135A5 (ru) | ||
| JP2016536321A5 (ru) | ||
| RU2019100065A (ru) | Кристаллы анилинпиримидинового соединения, действующего в качестве ингибитора EGFR | |
| RU2018126158A (ru) | Применение триацетил-3-гидроксифениладенозина для получения фармацевтического лекарственного средства для предупреждения или лечения неалкогольной жировой болезни печени | |
| RU2018128304A (ru) | Пиразоламидное соединение и его применения в медицине | |
| EA201391314A1 (ru) | Новое фенилпиридиновое производное и содержащее его лекарственное средство | |
| WO2013167997A3 (en) | Compositions and methods for the treatment of metabolic syndrome | |
| RU2018131500A (ru) | Кристаллические модификации гидрохлорида n-(4,5-бисметансульфонил-2-метилбензоил)гуанидина и солей n-(4,5-бисметансульфонил-2-метилбензоил)гуанидина | |
| EA202192269A3 (ru) | Жирные кислоты и их применение для конъюгации с биомолекулами |